Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

S Blach; S Zeuzem; M Manns; I Altraif; AS Duberg; DH Muljono; I Waked; SM Alavian; MH Lee; F Negro; F Abaalkhail; A Abdou; M Abdulla; A Abou Rached; I Aho; U Akarca; I Al Ghazzawi; S Al Kaabi; F Al Lawati; K Al Namaani; Y Al Serkal; SA Al-Busafi; L Al-Dabal; S Aleman; AS Alghamdi; AA Aljumah; HE Al-Romaihi; MI Andersson; V Arendt; P Arkkila; AM Assiri; O Baatarkhuu; A Bane; Z Ben-Ari; C Bergin; F Bessone; F Bihl; AR Bizri; M Blachier; AJ Blasco; CE Brandao Mello; P Bruggmann; CR Brunton; F Calinas; HLY Chan; A Chaudhry; H Cheinquer; CJ Chen; RN Chien; MS Choi; PB Christensen; WL Chuang; V Chulanov; L Cisneros; MR Clausen; ME Cramp; A Craxi; EA Croes; O Dalgard; JR Daruich; V De Ledinghen; GJ Dore; MH El-Sayed; G Ergor; G Esmat; C Estes; K Falconer; E Farag; MLG Ferraz; PR Ferreira; R Flisiak; S Frankova; I Gamkrelidze; E Gane; J Garcia-Samaniego; AG Khan; I Gountas; A Goldis; M Gottfredsson; J Grebely; M Gschwantler; M Guimaraes Pessoa; J Gunter; B Hajarizadeh; O Hajelssedig; S Hamid; W Hamoudi; A Hatzakis; SM Himatt; H Hofer; I Hrstic; YT Hui; B Hunyady; R Idilman; W Jafri; R Jahis; NZ Janjua; P Jarčuška; A Jeruma; JG Jonasson

Journal article

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, SM Alavian, MH Lee, F Negro, F Abaalkhail, A Abdou, M Abdulla, A Abou Rached, I Aho, U Akarca, I Al Ghazzawi, S Al Kaabi, F Al Lawati, K Al Namaani Show all

Lancet Gastroenterology and Hepatology | ELSEVIER INC | Published : 2017

DOI: 10.1016/S2468-1253(16)30181-9

Abstract

Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi p..

View full abstract